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Abstract
Characteristics of varicella-related hospitalizations in the mature varicella vaccination era, 
including the proportion vaccinated and the severity of disease, are not well described. We present 
the vaccination status, severity and reasons for hospitalization of the hospitalized varicella cases 
reported to the Los Angeles County Health Department from 2003 to 2011, the period which 
includes the last 4 years of the mature one-dose program and the first 5 years after introduction of 
the routine two-dose program. A total of 158 hospitalized varicella cases were reported overall, of 
which 52.5% were potentially preventable and eligible for vaccination, 41.8% were not eligible for 
vaccination, and 5.7% were vaccinated. Most hospitalizations (72.2%) occurred among healthy 
persons, 54.4% occurred among persons ≥20 years of age, and 3.8% of hospitalizations resulted in 
death. Our data suggest that as many as half of the hospitalized varicella cases, including half of 
the deaths, may have been preventable given that they occurred in persons who were eligible for 
vaccination. More complete implementation of the routine varicella vaccination program could 
further reduce the disease burden of severe varicella.
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1. Introduction
Although often a mild disease of childhood, varicella can result in serious morbidity and 
mortality. Increasing age and chronic co-morbid conditions have been identified as risk 
factors for severe varicella [1–4]; however, before introduction of the varicella vaccine in 
1995, over half of varicella hospitalizations were in previously healthy children less than 15 
years of age [1]. Following the one-dose varicella vaccine recommendation for children by 
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the Advisory Committee on Immunization Practices (ACIP) in 1996 [5], the number of 
hospitalizations due to varicella declined 67%, with the majority of hospitalizations still 
occurring among previously healthy persons [2,6–10]. In 2001, California implemented a 
one-dose school entry requirement for varicella vaccine that is now required for all students 
entering grades K-12. In 2006, a routine two-dose varicella vaccination program was 
implemented in the United States to further reduce varicella disease and its complications 
[11].
Declines in the number of varicella-related hospitalizations during the early years of the 
two-dose varicella vaccination program have been documented [12]. However, 
characteristics of varicella-related hospitalizations in the mature varicella vaccination era, 
including the proportion vaccinated and the severity of disease, are not well described. This 
study describes the vaccination status, severity, and reasons for hospitalization for varicella 
hospitalizations among cases reported to the Los Angeles County Health Department from 
2003 to 2011, a period that includes the last 4 years of the mature one-dose program and the 
first 5 years after introduction of the routine two-dose program. Understanding the 
characteristics of cases requiring hospitalization will help inform strategies for further 
reducing severe disease.
2. Methods
The Los Angeles County Department of Public Health (LACDPH) has collected information 
on cases of hospitalized varicella in Los Angeles County since it was added to the California 
Code of Regulations as a reportable condition in 2003. The study population included all 
hospitalized varicella cases residing in Los Angeles County reported to the LACDPH with 
disease onset between January 1, 2003 and December 31, 2011. As part of mandated public 
health investigations, data on patient demographics, medical history, vaccination history, and 
clinical course were abstracted by health department staff from hospital records for each 
case.
2.1. Definitions
A probable case of varicella was defined as an acute illness with diffuse (generalized) 
maculopapulovesicular rash without laboratory confirmation or an epidemiologic linkage to 
another probable or confirmed case [13]. A confirmed case of varicella was defined as an 
acute illness with diffuse (generalized) maculopapulovesicular rash and either laboratory 
confirmation of varicella or epidemiologic linkage to another probable or confirmed case 
[13]. A varicella-related hospitalization was defined as a probable or confirmed case of 
varicella that was hospitalized for at least 24 h.
Cases were categorized as being hospitalized for precautionary reasons if they had a chronic 
condition that resulted in the hospitalization without which they would otherwise not be 
hospitalized. Cases were categorized as hospitalized for varicella if they had severe 
varicella-related symptoms, such as fever or profuse rash, which required hospitalization. 
Cases were categorized as hospitalized for varicella-related complications if the disease 
resulted in a complication which required hospitalization.
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Reported varicella-related complications were categorized as: pulmonary (including 
pneumonia, respiratory failure, bronchiolitis), dermatologic (including secondary skin 
infections, cellulitis, impetigo), bacteremia/sepsis, dehydration, and neurologic (including 
encephalitis, cerebellar ataxia, meningitis, altered level of consciousness, seizures). Cases 
could have multiple complications.
Chronic conditions were health conditions present before hospitalization and were 
categorized as: immunocompromised (including cancer, HIV/AIDS, previous organ 
transplant, autoimmune disorder), chronic renal failure, chronic lung disease, diabetes, and 
asthma. Cases could have multiple chronic conditions.
Cases were categorized as vaccinated if they had documented proof (e.g., immunization 
record) of previous vaccination with at least one dose of varicella-containing vaccine. Cases 
were considered as breakthrough varicella if they developed varicella 42 or more days after 
vaccination. Cases were classified as potentially preventable if they did not fall into one of 
the following categories: had documented proof of previous varicella disease, had been 
vaccinated with at least one dose of varicella-containing vaccine, or were 
immunocompromised. Cases in pregnant women were considered as potentially preventable 
if they had not been previously vaccinated with at least one dose of varicella-containing 
vaccine before pregnancy.
2.2. Data analysis
Data were analyzed using SAS 9.2 software (SAS Institute Inc., Cary, NC). Poisson 
regression analysis was used to compare overall hospitalization rates and rates by age group 
between the mature one-dose (2003–2006) and the early two-dose (2007–2011) varicella 
vaccination eras.
3. Results
A total of 369 suspected cases of varicella that required hospitalization were reported in Los 
Angeles County with disease onset between 2003 and 2011. After excluding 39 (10.6%) that 
were determined to be herpes zoster and 172 (46.6%) determined not to be varicella, 158 
(42.8%) varicella hospitalizations were included in the analysis. Sixty-nine of the 
hospitalized varicella cases were reported during 2003–2006 and 89 during 2007–2011, after 
implementation of the routine two-dose varicella vaccine program era, with a rate of 0.2 
hospitalized varicella cases/100,000 population during each era, 2003–2006 and 2007–2011 
(p = 0.9). No statistically significant differences between hospitalization rates by vaccination 
program era were identified for any of the age groups (data not shown). Demographic and 
hospitalization characteristics of the cases are presented in Table 1. The median number of 
days hospitalized was 5 (range 1–174). Just over half (54.4%) of the hospitalized cases were 
≥20 years of age; 16 (10.1%) were pregnant. Most hospitalizations (72.2%) occurred among 
healthy persons. Twenty-seven (17.1%) hospitalized varicella cases whose country of birth 
was known were born outside of the United States: 15 in Asia and 12 in Central/South 
America. Of these foreign-born cases, 5 (18.5%) were pregnant and 12 (44.4%) had chronic 
conditions prior to hospitalization. Nine (5.7%) hospitalized varicella cases had 
documentation of at least one dose of varicella vaccination. Six (3.8%) case-patients died.
Agopian et al. Page 3













Data on vaccination status and place of birth were missing for 52% of cases while 48% of 
cases were missing information on laboratory confirmation. Less than 5% of cases were 
missing data on race/ethnicity or chronic health conditions.
3.1. Potentially preventable hospitalizations
Of the 83 (52.5%) hospitalized varicella cases that were potentially preventable, 23 (27.7%) 
were 1–19 years of age, and 60 (72.3%) were ≥20 years of age. Twenty-seven (32.5%) of the 
potentially preventable cases were laboratory confirmed. Of those whose country of birth 
was known, 21 were born in the United States, 3 in Mexico, 12 in Asia, and 6 in Central/
South America. Twenty-three (27.7%) were admitted for precautionary reasons, of which 15 
(65.2%) were pregnant; 56 (67.5%) were admitted for varicella or varicella-related 
complications; and 4 (4.8%) for other medical conditions (i.e., atrial fibrillation, heart 
surgery, alcohol withdrawal, shunt infection) who were incubating disease upon admission. 
Thirty-five (42.2%) of the hospitalized varicella cases that were potentially preventable 
experienced at least one varicella complication, including pulmonary (15), neurologic (5), 
and dermatologic (5) complications, bacteremia (3) and dehydration (3). Three of the 
potentially preventable hospitalizations resulted in death; one occurred in a 1 year old child 
who was scheduled for vaccination and experienced bacteremia and dehydration and 2 were 
≥20 years of age.
3.2. Hospitalizations among persons not eligible for vaccination
A total of 66 (41.8%) varicella cases among persons not eligible for vaccination were 
hospitalized, including 25 (37.9%) who were <1 year of age (14 were <6 months and 11 
were 6–11 months of age) and 41 (62.1%) who were immunocompromised. Twenty-two 
(33.3%) of the cases ineligible for vaccination were laboratory confirmed. Reasons for 
admission among the cases that were not eligible for vaccination included: 28 (42.4%) for 
varicella or varicella-related complications, including 6 infants <6 months and 8 infants 6–
11 months of age; 37 (56.1%) for precautionary reasons, including 8 infants <6 months and 
3 infants 6–11 months of age; and 1 (1.5%) that developed varicella while hospitalized for a 
liver transplant. Thirty-one (47.0%) of the cases not eligible for vaccination developed at 
least one complication, including dermatologic (12), pulmonary (10), and neurologic (4) 
complications, bacteremia (3), and dehydration (1). Three of the hospitalizations that 
occurred among persons not eligible for vaccination resulted in death; all were ≥20 years of 
age and immunocompromised.
3.3. Hospitalizations among vaccinated persons
Nine (5.7%) of the hospitalized varicella cases had been vaccinated against varicella; one 
(11.1%) was laboratory confirmed. All were children, of whom two were 1–4 years of age 
and seven were 11–14 years of age. Seven (77.8%) of the cases had received one dose and 2 
(22.2%) had received two doses of varicella-containing vaccine. Seven of the cases were 
considered breakthrough varicella and two developed a rash within 42 days of vaccination. 
Four of the vaccinated cases were immunocompromised; each had received one dose of 
varicella-containing vaccine. Five (71.4%) of the vaccinated cases that had received one 
dose were hospitalized for precautionary reasons and 2 (28.6%) for varicella or varicella-
related complications. The two case-patients that had received two doses of varicella-
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containing vaccine were admitted for cellulitis. None of the hospitalized vaccinated cases 
resulted in death.
4. Discussion
While varicella is often a self-limiting disease, it can be severe, requiring hospitalization and 
resulting in death. Varicella-related hospitalizations decreased by 65% in all age groups 
during the one-dose varicella vaccination era and additional declines have been reported 
since implementation of the two-dose program [12,14]. Our descriptive data on hospitalized 
cases of varicella in Los Angeles County demonstrate that, as in the prevaccination era, most 
hospitalized cases of varicella continue to occur among previously healthy persons with no 
immunocompromising conditions. Although the population under surveillance in our study 
may have been too small to detect differences in the rate of hospitalization between the 
mature one-dose and early two-dose varicella vaccination program eras, our data suggest 
that as many as half of hospitalized varicella cases, including half of the deaths, may have 
been preventable given that they occurred in persons who were eligible for vaccination. 
More complete implementation of the routine varicella vaccination program could further 
reduce the disease burden of severe varicella.
Varicella-related hospitalizations declined in all age groups during the one-dose era 
including among 0–4 year olds suggesting a benefit of the vaccination program among those 
too young to be fully vaccinated [2,6–9,12]. We did not document a decline in infant 
hospitalization rates in our study but it appeared that younger infants were more often 
hospitalized for precautionary reasons compared with older infants who were more likely to 
be hospitalized for severe disease. However, this difference was not statistically significant. 
Younger infants may benefit from protection provided by maternal antibodies, which start to 
wane after the first few months of life, and therefore may experience less severe disease 
compared with older infants [15]. Hospitalizations among infants continue to occur in the 
varicella vaccination era and these findings highlight the importance of vaccinating close 
contacts of individuals unable to receive varicella vaccine due to age or contraindication 
[11].
We identified a small number of varicella cases that resulted in hospitalization among 
children who had received varicella vaccine. Half of these cases were in children with 
immunocompromising conditions, none of whom had received two doses. An estimated 15–
20% of children may not respond to a single dose of varicella vaccine [16]. Whether these 
hospitalizations could have been prevented had these children received two doses of 
varicella vaccine prior to becoming immunocompromised is not known, but it highlights the 
importance of receiving vaccinations on schedule. Three of the hospitalized varicella cases 
among previously healthy children that were vaccinated, including the two who had received 
two doses, appeared to be severe. While the data to date indicate that severe breakthrough 
varicella is rare, ongoing monitoring of varicella hospitalizations will be important for 
providing a better understanding of the potential for severe breakthrough varicella.
Although declines of varicella hospitalizations among adults have been demonstrated during 
the early two-dose varicella vaccination era [12], rates of hospitalizations among adults in 
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Los Angeles County did not change over time (data not shown). Many of the adult 
hospitalized cases in Los Angeles County were admitted for precautionary reasons, 
including several that were pregnant. These cases highlight the importance of high 
vaccination coverage and catch-up vaccination to ensure that adolescents and adults are 
protected as varicella can be more severe in adulthood and during pregnancy. Prenatal 
assessment of women for evidence of varicella immunity is recommended with vaccination 
of susceptible individuals prior to or upon completion of pregnancy [11]. Additionally, 
several of the hospitalized cases among adults were in persons who were foreign-born. It is 
important for clinicians to remember that the epidemiology of varicella is different in 
tropical countries and foreign-born adults should not be assumed to be protected against 
varicella [17].
There were limitations to our study. A majority of the potentially preventable 
hospitalizations that we identified occurred in persons ≥20 years of age. However, due to 
challenges of diagnosis of varicella in adults, particularly those ≥50 years of age in whom it 
can be difficult to clinically distinguish herpes zoster from varicella, the total number of 
hospitalized cases and those that were potentially preventable may be an overestimate. Data 
on severity of varicella, based on lesion count, and indications for hospitalization were not 
systematically documented in the medical charts and thus were not available for all cases. 
Furthermore, more than 50% of cases were missing information on vaccination status which 
may have led to an underestimation of the number of hospitalizations among vaccinated 
persons.
Given that many hospitalizations in the mature varicella vaccination program appear to be 
precautionary, it will be important to consider changes in clinical management and 
indications for hospitalization as varicella becomes less common since this may confound 
use of hospitalization data to track severe varicella disease going forward. We found that 
more than half of the varicella hospitalizations in Los Angeles County during the varicella 
vaccination era, 2003–2011, were potentially preventable with vaccination. Moreover, more 
than half occurred among adults, suggesting that additional efforts are needed to identify and 
target susceptible adolescents and adults for varicella vaccination. Our study identified few 
hospitalizations among vaccinated persons but additional years of data are needed to 
determine the impact of the two-dose varicella vaccination program on varicella 
hospitalizations. More complete implementation of the routine varicella vaccination program 
could further reduce the disease burden of severe varicella.
No special funding was secured for this study. The findings and conclusions in this report 
are those of the authors and do not necessarily represent the official position of the Centers 
for Disease Control and Prevention.
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Table 1
Demographic and clinical characteristics of reported hospitalized varicella cases, Los Angeles County, 2003–
2011, n = 158.
Characteristics Potentially preventable
hospitalizations (N = 83) n (%)
Hospitalizations in persons not
eligible for vaccination (N = 66) n 
(%)
Hospitalizations in vaccinated
personsa (N = 9) n (%)
Gender
  Male 42 (50.6) 40 (60.6) 7 (77.8)
  Female 41 (49.4) 26 (39.4) 2 (22.2)
Age
  <1 0 25 (37.9) 0
  1–4 7 (8.4) 4 (6.1) 2 (22.2)
  5–9 4 (4.8) 2 (3.0) 5 (55.6)
  10–14 4 (4.8) 6 (9.1) 2 (22.2)
  15–19 8 (9.6) 3 (4.5) 0
  20–49 48 (57.8) 14 (21.2) 0
  50+ 12 (14.5) 12 (18.2) 0
Race/ethnicitya
  Hispanic 37 (44.6) 39 (59.1) 5 (55.6)
  White 22 (26.5) 7 (10.6) 0
  Asian/Pacific Islander 14 (16.9) 9 (13.6) 2 (22.2)
  African American/Black 7 (8.4) 8 (12.1) 1 (11.1)
  Unknown 3 (3.6) 3 (4.5) 1 (11.1)
Reasons for admission
  Precautionary 23 (27.7) 37 (56.1) 5 (55.6)
  Varicella-related complications 31 (37.3) 19 (28.8) 2 (22.2)
  Varicella 25 (30.1) 9 (13.6) 1 (11.1)
  Other 4 (4.8) 1 (1.5) 1 (11.1)
Varicella-related complications
  Yes 35 (42.2) 30 (45.4) 4 (44.4)
  No 48 (57.8) 36 (54.5) 5 (55.6)
Laboratory confirmation
  Yes 27 (32.5) 22 (33.3) 1 (11.1)
  No 17 (20.5) 13 (19.7) 3 (33.3)
  Unknown 39 (47.0) 31 (47.0) 5 (55.6)
Died
  Yes 3 (3.6) 3 (4.5) 0
  No 80 (96.4) 63 (95.5) 9 (100)
a
Data for vaccination status and race/ethnicity were missing for 51.3% and 4.4% of cases, respectively.
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